SCHEMBL6927417

SCHEMBL6927417

COC(=O)c1cnccc1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.58
SRC P12931 1/20 0.58
FGFR2 P21802 1/20 0.58
FGFR4 P22455 1/20 0.58
FGFR3 P22607 1/20 0.58
CYP46A1 Q9Y6A2 1/20 0.54
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
SLC6A3 Q01959 3/20 0.50
SLC6A4 P31645 2/20 0.50
MAPK1 P28482 1/20 0.50
GABRA1 P14867 2/20 0.49
GABRG2 P18507 2/20 0.49
GABRB3 P28472 2/20 0.49
GABRA3 P34903 2/20 0.49
GABRA5 P31644 1/20 0.49
PDCD1 Q15116 1/20 0.48
CD274 Q9NZQ7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29108469 0.90 CYP46A1 (0.65) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL30640092 0.90 CYP46A1 (0.65) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL5740654 0.86 CYP46A1 (0.64) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL5905310 0.84 SLC6A3 (0.63) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL27880534 0.83 PDCD1 (0.50) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL28296099 0.83 SMN1; SMN2 (0.53) ALDH1A1KDM4EGAAMAPK1KMT2A
Isoquinoline SCHEMBL28038146 0.83 SLC6A3 (0.58) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL6641437 0.81 ALDH1A1 (0.50) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL2222831 0.81 ALDH1A1 (0.50) CYP46A1ALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL29644805 0.81 KMT2A (0.61) ALDH1A1KDM4EGLAGAASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed
US-4904675-A Phamacologically active 5-carboxy-2-(5-tetrazolyl) pyridines ZYMA SA (CH) 1990-02-27 US disclosed
EP-0278908-A2 Heterocyclic compounds Zyma SA (CH) 1988-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI FGFR1 2986/4885SRC 782/4885FGFR2 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.